Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6764370 | 0.92 | SYK (0.41) | SYKPOLBMAPTPPARAMEN1 | |
| SCHEMBL6764374 | 0.92 | SYK (0.41) | SYKPOLBMAPTPPARAMEN1 | |
| SCHEMBL670165 | 0.89 | POLB (0.43) | POLBSMN1; SMN2ATMNPC1RAB9A | |
| SCHEMBL5567091 | 0.89 | POLB (0.43) | POLBSMN1; SMN2ATMNPC1RAB9A | |
| SCHEMBL670164 | 0.89 | POLB (0.43) | POLBSMN1; SMN2ATMNPC1RAB9A | |
| SCHEMBL8196306 | 0.86 | POLB (0.44) | POLBSMN1; SMN2ATMNPC1RAB9A | |
| SCHEMBL22798569 | 0.86 | POLB (0.44) | POLBSMN1; SMN2ATMNPC1RAB9A | |
| SCHEMBL8199752 | 0.85 | ADRB2 (0.33) | KMT2A | |
| SCHEMBL8121 | 0.83 | RAB9A (0.32) | RAB9A | |
| SCHEMBL13221 | 0.83 | RAB9A (0.32) | RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | TANABE SEIYAKU CO., LTD. (JP) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106635-A1 | having small-conductance potassium channel (SK) blocking activity | KCNN1, KCNN2, KCNN3 | SYK 2524/4885POLB 3058/4885SMN1; SMN2 3337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.